58 related articles for article (PubMed ID: 483710)
1. [Nephrotoxicity mechanisms of the antitumor preparation, cis-dichlorodiammineplatinum].
Belkin AL; Sidorik OA; Pendrak KA; Povzhitkova MS; Osadchaia LP
Vopr Onkol; 1979; 25(8):95-6. PubMed ID: 483710
[No Abstract] [Full Text] [Related]
2. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Yuhas JM; Culo F
Cancer Treat Rep; 1980 Jan; 64(1):57-64. PubMed ID: 6247064
[TBL] [Abstract][Full Text] [Related]
3. [Modification of the toxic effects of cis-dichlorodiammineplatinum].
Kulik GI; Chekhun VF; Pel'kis FP; Korol' VI; Boĭm TM
Eksp Onkol; 1985; 7(6):55-8. PubMed ID: 4085400
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of cis-dichlorodiammineplatinum(II).
Krakoff IH
Cancer Treat Rep; 1979; 63(9-10):1523-5. PubMed ID: 498152
[No Abstract] [Full Text] [Related]
5. cis-Dichlorodiammineplatinum nephrotoxicity in rats of different ages.
Braunlich H; Kuo CH; Slocombe R; Hook JB
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):279-91. PubMed ID: 6539942
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of cis-dichlorodiammineplatinum(II).
Wolpert-DeFilippes MK
Cancer Treat Rep; 1979; 63(9-10):1453-8. PubMed ID: 498146
[TBL] [Abstract][Full Text] [Related]
7. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.
Bergerat JP; Drewinko B; Corry P; Barlogie B; Ho DH
Cancer Res; 1981 Jan; 41(1):25-30. PubMed ID: 7192598
[TBL] [Abstract][Full Text] [Related]
8. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
10. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic cisplatin nephropathy in rats.
Choie DD; Longnecker DS; del Campo AA
Lab Invest; 1981 May; 44(5):397-402. PubMed ID: 7194946
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
Howell SB; Taetle R
Cancer Treat Rep; 1980; 64(4-5):611-6. PubMed ID: 7191778
[TBL] [Abstract][Full Text] [Related]
15. Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats.
Ward JM; Grabin ME; LeRoy AF; Young DM
Cancer Treat Rep; 1977; 61(3):375-9. PubMed ID: 872137
[No Abstract] [Full Text] [Related]
16. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.
Levi FA; Hrushesky WJ; Blomquist CH; Lakatua DJ; Haus E; Halberg F; Kennedy BJ
Cancer Res; 1982 Mar; 42(3):950-5. PubMed ID: 7199382
[TBL] [Abstract][Full Text] [Related]
17. Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation.
Kohda Y; Kawai Y; Iwamoto N; Matsunaga Y; Aiga H; Awaya A; Gemba M
Biochem Pharmacol; 2005 Nov; 70(9):1408-16. PubMed ID: 16154539
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological blockade of the nephrotoxicity of cisplatin in rats].
Natochin IuV; Raznik LV; Bakhteeva VT; Ivanov VB; Miazina EM
Biull Eksp Biol Med; 1986 Oct; 102(10):442-5. PubMed ID: 3768510
[TBL] [Abstract][Full Text] [Related]
19. [Nonspecific oxidase activity in the liver of rats undergoing chemotherapy with cis-dichlorodiammineplatinum].
Kulik GI; Pel'kis FP; Chekhun VF; Sidorik OA; Boĭm TM
Eksp Onkol; 1984; 6(6):60-3. PubMed ID: 6543174
[TBL] [Abstract][Full Text] [Related]
20. Parathyroidectomy has a beneficial effect on experimental cisplatin nephrotoxicity.
Capasso G; Giordano DR; de Tommaso G; De Santo NG; Massry SG
Clin Nephrol; 1990 Apr; 33(4):184-91. PubMed ID: 2350906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
